Daiichi Sankyo Receives Untitled Letter for False Efficacy Claims

A A
The FDA has handed Daiichi Sankyo an untitled letter for making claims in a brochure that two of its hypertension treatments helped lower blood pressure in patients with severe hypertension, despite a lack of substantial supportive evidence.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00